Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16940459 | 0.93 | ITGB3 (0.51) | ITGB3ITGA2BLTA4HS1PR4S1PR1 | |
| SCHEMBL6871466 | 0.90 | ITGB3 (0.51) | ITGB3ITGA2BLTA4HL3MBTL1S1PR4 | |
| SCHEMBL7358634 | 0.89 | ACACB (0.50) | ITGB3ITGA2BLTA4HPTPN1 | |
| SCHEMBL9995960 | 0.87 | NPC1 (0.54) | ITGB3ITGA2BS1PR4S1PR1S1PR3 | |
| SCHEMBL9995958 | 0.87 | NPC1 (0.54) | ITGB3ITGA2BS1PR4S1PR1S1PR3 | |
| SCHEMBL6286612 | 0.86 | LTA4H (0.47) | ITGB3ITGA2BLTA4HPTPN1 | |
| SCHEMBL16173552 | 0.86 | LTA4H (0.46) | ITGB3ITGA2BLTA4HPTPN1 | |
| SCHEMBL14405380 | 0.86 | LTA4H (0.46) | ITGB3ITGA2BLTA4HPTPN1 | |
| Hydrochloric Acid SCHEMBL5174869 | 0.85 | LTA4H (0.46) | ITGB3ITGA2BLTA4HPTPN1 | |
| Acetic Acid SCHEMBL6866559 | 0.85 | ITGB3 (0.47) | ITGB3ITGA2BLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703825-B2 | Compounds, use thereof as medicaments, and method of preparation thereof | UNIVERSITE DE LORRAINE (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110184070-A1 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF | UNIVERSITE HENRI POINCARE NANCY 1 (FR) | 2011-07-28 | — | — | US | disclosed |
| EP-2303837-A2 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD FOR THE PREPARATION THEREOF | Université Henri Poincaré Nancy 1 (FR) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010004231-A2 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD FOR THE PREPARATION THEREOF | UNIVERSITE HENRI POINCARE NANCY 1 (FR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184070-A1 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF | CYP11B2, NPM1, B2M | ITGB3 1438/4885ITGA2B 3035/4885GAA 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.